Sanofi (SNYNF)
| Market Cap | 118.83B |
| Revenue (ttm) | 53.71B |
| Net Income (ttm) | 10.72B |
| Shares Out | n/a |
| EPS (ttm) | 8.65 |
| PE Ratio | 11.09 |
| Forward PE | 10.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102 |
| Average Volume | 105,927 |
| Open | 98.12 |
| Previous Close | 97.64 |
| Day's Range | 98.12 - 98.12 |
| 52-Week Range | 91.00 - 122.03 |
| Beta | 0.41 |
| RSI | 43.81 |
| Earnings Date | Jul 31, 2025 |
About Sanofi
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Sanofi: Playing To Win
Emcure Pharmaceuticals Reports Strong Q1 FY26 Results with 16% Revenue Growth and 41% Jump in Profit
Emcure Pharmaceuticals reported a strong Q1 FY26 performance with a 15.7% YoY rise in revenue to ₹2,101 crore and a 41% jump in PAT to ₹215 crore. Robust growth was seen across both domestic and inter...
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”).
What's Driving the Market Sentiment Around Sanofi?
Sanofi's (NYSE: SNY) short percent of float has fallen 15.0% since its last report. The company recently reported that it has 3.67 million shares sold short , which is 0.17% of all regular shares tha...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Arrowhead unit sells rights for plozasiran to Sanofi in Greater China
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Sanofi (SNY) Q2 2025 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ETCompany ParticipantsBrian Foard - Executive VP & Head of Specialty...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Press release: Online availability of Sanofi's half-year financial report for 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025. Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and ...
Press release: Online availability of Sanofi's half-year financial report for 2025
Online availability of Sanofi's half-year financial report for 2025 Paris, July 31, 2025 . Sanofi announces that its half-year financial report for the period ending June 30, 2025 is now available and...
Sanofi 2025 Q2 - Results - Earnings Call Presentation
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi SA SNY reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.
Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales
Sanofi SA (NASDAQ: SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion . Sales increased 6% year over year, up 10.1% in consta...
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi CEO Paul Hudson on Q2 results, Dupixent demand and tariff impact
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.
Sanofi revises annual sales growth expectations on strong Dupixent demand
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong demand for its anti-inflammatory drug Dupixent, as well as vaccines and newer tr...
Sanofi gives Q2 results
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range.
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment...